<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30194175</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>19</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>19</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Radiation Therapy for Positive Surgical Margins in Women ≥70 Years with Stage I, Estrogen Receptor-positive Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>5253-5260</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12850</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">A re-excision for positive margin(s) following a lumpectomy for invasive breast cancer is a standard recommendation. However, for elderly women with stage I estrogen receptor-positive (ER+) tumors, who may be at higher surgical risk, whether radiation therapy without re-excision will be adequate is not known.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We evaluated a cohort of 53,950 women aged ≥70 years with Stage I, ER+ breast cancer who had lumpectomy and anti-hormone therapy diagnosed between 2004 and 2011 in the National Cancer Data Base. Patients were divided into four groups: 1) negative margins without radiation (XRT), 2) negative margins with XRT, 3) positive margins without XRT, and 4) positive margins with XRT. Clinicopathological and sociodemographic variables were compared among these groups. Univariable and multivariable analysis were employed.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year overall survival (OS) rates for the groups were as follows: 1) negative margins without radiation (XRT); 77.1%, 2) negative margins with XRT; 90.0%, 3) positive margins without XRT; 62.9%, and 4) positive margins with XRT; 86.8% (p&lt;0.0001). Significant predictors (p&lt;0.01) of OS include treatment groups, age, income status, facility type, facility location, tumor size, tumor grade, and comorbidities.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Radiation therapy for positive surgical margins without re-excision may be a viable option for elderly women with stage I, ER+ tumor treated with lumpectomy and hormonal therapy.</AbstractText>                <CopyrightInformation>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Meijiao</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Louisiana Tumor Registry &amp; Biostatistics and LTR &amp; Epidemiology, Louisiana State University Health Sciences Center, New Orleans, LA, U.S.A.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peddi</LastName>                    <ForeName>Prakash</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Willis Knighton Cancer Center, Shreveport, LA, U.S.A.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chu</LastName>                    <ForeName>Quyen D</ForeName>                    <Initials>QD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, U.S.A. qchu@lsuhsc.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Feist-Weiller Cancer Center, Shreveport, LA, U.S.A.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072662" MajorTopicYN="N">Margins of Excision</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Elderly breast cancer</Keyword>            <Keyword MajorTopicYN="N">radiation therapy</Keyword>            <Keyword MajorTopicYN="N">stage I breast cancer</Keyword>            <Keyword MajorTopicYN="N">surgical margins</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30194175</ArticleId>            <ArticleId IdType="pii">38/9/5253</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12850</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>